Ono H, Sakamoto A, Sakura N
Understanding your levels helps tailor your approach to supplementation
Abstract Alcohol use disorders are among the top causes of the global burden of disease, yet therapeutic interventions are limited
1 Dual agonism of GIP and GLP-1 receptors is a promising new approach currently in clinical development for the treatment of diabetes, obesity, and associated complications [1] The incretin effect defines the main physiological role of GIP and GLP-1 GIP and GLP-1 increase insulin secretion following nutrient-induced secretion from the gut (incretin effect): There is a stronger insulin secretion response to oral compared to 'isoglycemic' intravenous glucose administration due to secretion and action of incretin hormones
Prior authorization requirements for specific medications to ensure that the prescribing doctor has determined that a medication is necessary to treat a member, based on specific medical standards
Spurzem JR, Bonekat HW, Shigeoka JW